МЕДИКАМЕНТОЗНОЕ ЛЕЧЕНИЕ БОЛЬНЫХ С НЕЙРОГЕННОЙ ГИПЕРАКТИВНОСТЬЮ МОЧЕВОГО ПУЗЫРЯ
https://doi.org/10.24884/1561-6274-2012-16-1-57-62
Аннотация
Гиперактивность мочевого пузыря (ГАМП) является одной из наиболее частых дисфункций нижних мочевых путей и клинически проявляется императивными позывами, учащением мочеиспускания и ургентным недержанием мочи. Антихолинергические препараты являются основой терапии больных с нейрогенной ГАМП. Они увеличивают емкость мочевого пузыря, снижают внутрипузырное давление, уменьшают интенсивность симптоматики ГАМП. Больным с нейрогенной ГАМП часто требуется назначать дозы антихолинергических препаратов, существенно превышающие таковые при лечении пациентов с идиопатической ГАМП. Кроме того, возможно комбинированное применение нескольких антихолинергических препаратов. Неэффективность или плохая переносимость пероральной медикаментозной терапии является показанием к внутрипузырному введению нейротоксинов, в первую очередь, ботулинического токсина.
Об авторах
С.Х. Аль-Шукри
Санкт-Петербургский государственный медицинский университет им. акад. И.П.Павлова
Россия
Кафедра урологии
Россия
Кафедра урологии
И. В. Кузьмин
Санкт-Петербургский государственный медицинский университет им. акад. И.П.Павлова
Россия
Россия
Кафедра урологии
197022, Санкт-Петербург, ул. Льва Толстого, д. 17, тел. (812) 234-19-54
Е. Е. Лукина
Санкт-Петербургский государственный медицинский университет им. акад. И.П.Павлова
Россия
Кафедра урологии
Россия
Кафедра урологии
Список литературы
1. Abrams P, Cardozo L, Fall M et al. The standartisation of terminology in lower urinary tract function: Report from the standartisation sub-committee of the International Continence Society. Neurourol Urodyn 2003; 21: 167-178
2. Hunskaar S, Arnold EP, Burgio K et al. Epidemiology and natural history of urinary incontinence. In: Abrams P, Cardozo L, Khoury S, Wein A, eds. Incontinence: 2st International Consultation on Incontinence, July 1-3, 2002, 2nd ed. Health Publication Ltd, Plymouth, UK, 2002; 167-201
3. De Groat WC. A neurologic basis for the overactive bladder. Urology 1997; 50 (6A Suppl): 36-52
4. De Groat WC, Booth AM, Yoshimura N. Neurophysiology of micturition and its modification in animal models of human disease. In: Maggi CA, ed. The autonomic nervous system, Vol.3, Chapter 8, Nervous control of the urogenital system. Harwood Academic Publishers, London, UK, 1993: 227-290
5. Stöhrer М, Blok B, Castro-Diaz D.et al. EAU Guidelines on Neurogenic Lower Urinary Tract Dysfunction. Eur Urol 2009; 56 (1): 81-88
6. Donnelly J, Hackler RH, Bunts RC. Present urologic status of the World War II paraplegic: 25-year follow-up. Comparison with status of the 20-year Korean War paraplegic and 5-year Vietnam paraplegic. J Urol 1972; 108 (4): 558-562
7. Game X, Castel-Lacanal E, Bentaleb Y et al. Botulinum toxin A detrusor injections in patients with neurogenic detrusor overactivity significantly decrease the incidence of symptomatic urinary tract infections. Eur Urol 2007; 53 (3): 613-619
8. Castro-Diaz D, Barrett D, Grise P et al. Surgery for the neuropathic patient. In: Abrams P, Cardozo L, Khoury S, Wein A, eds. Incontinence: 2st International Consultation on Incontinence, July 1-3, 2002, 2nd ed. Health Publication Ltd, Plymouth, UK, 2002; 865-891
9. Appell RA. Overactive bladder in special patient populations. Rev Urol 2003; 5 (8): 37-41
10. Chancellor MB, Anderson RU, Boone TB. Pharmacotherapy for neurogenic detrusor overactivity. Am J Phys Med Rehabil 2006; 85: 536–545
11. Diokno A, Ingber M. Oxybutynin in detrusor overactivity. Urol Clin N Am 2006; 33 (4): 439-445
12. O’Leary M, Erickson JR, Smith CP et al. Effect of controlledrelease oxybutynin on neurogenic bladder function in spinal cord injury. J Spinal Cord Med 2003; 26 (2): 159-162
13. Bennett N, O’Leary M, Patel AS et al. Can higher doses of oxybutynin improve efficacy in neurogenic bladder? J Urol 2004; 171 (2 Pt 1): 749-751
14. Kennelly MJ, Lemack GE, Foote JE, Trop CS. Efficacy and safety of oxybutynin transdermal system in spinal cord injury patients with neurogenic detrusor overactivity and incontinence: an open-label, dose-titration study. Urology 2009; 74 (4): 741-745
15. Stohrer M, Murtz G, Kramer G et al. Propiverine compared to oxybutynin in neurogenic detrusor overactivity – results of a randomized, doubleblind, multicenter clinical study. Eur Urol 2007; 51 (1): 235–242
16. Wyndaele JJ, Castro D, Madersbacher H et al. Neurologic urinary and fecal incontinence. In: Abrams P, Cardozo L, Khoury S, Wein A, eds. Incontinence, Vol.2. Health Publication Ltd, Plymouth, UK, 2005; 1059–1062
17. Lehtoranta K, Tainio H, Lukkari-Lax E et al. Pharmacokinetics, efficacy, and safety of intravesical formulation of oxybutynin in patients with detrusor overactivity. Scand J Urol Nephrol 2002; 36(1): 18-24
18. Ethans KD, Nance PW, Bard RJ et al. Efficacy and safety of tolterodine in people with neurogenic detrusor overactivity. J Spinal Cord Med 2004; 27: 214–218
19. Horstmann M, Schaefer T, Aguilar Y et al. Neurogenic bladder treatment by doubling the recommended antimuscarinic dosage. Neurourol Urodyn 2006; 25 (5): 441-445
20. Menarini M, Del Popolo G, Di Benedetto P et al. Trospium chloride in patients with neurogenic detrusor overactivity: is dose titration of benefit to the patients? Int J Clin Pharmacol Ther 2006; 44(12): 623-632
21. Stöhrer M, Bauer P, Giannetti BM et al. Effect of trospium chloride on urodynamic parameters in patients with detrusor hyperreflexia due to spinal cord injuries. A multicentre placebocontrolled double-blind trial. Urol Int 1991; 47 (3): 138-143
22. Bycroft J, Leaker B, Wood S et al. The effect of darifenacin on neurogenic detrusor overactivity in patients with spinal cord injury. In: Proceedings of 33st Annual Meeting of International Continence Society. Florence, Italy, 2003; Abstract 190
23. Carl S, Laschke S. Darifenacin is also effective in neurogenic bladder dysfunction (multiple sclerosis). Urology 2006; 68 [suppl]: 250
24. Chapple CR, Araño P, Bosch JL et al. Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dosefinding study. BJU Int 2004; 93: 71–77
25. Cardozo L, Lisec M, Millard R et al. Randomized, doubleblind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol 2004; 172: 1919–1924
26. Suzuki M, Ohtake A, Yoshino T et al. Effects of solifenacin succinate (YM905) on detrusor overactivity in conscious cerebral infracted rats. Eur J Pharmacol 2005; 512 (1): 61–66
27. Fowler CJ, Griffiths D, De Groat WC. The neural control of micturition. Nat Rev Neurosci 2008; 9 (6): 453-466
28. Braverman AS, Luthin GR, Ruggieri MR. M2 muscarinic receptor contributes to contraction of the denervated rat urinary bladder. Am J Physiol 1998; 275 (5): 1654-1660
29. Amend B, Hennenlotter J, Schäfer T el. Effective treatment of neurogenic detrusor dysfunction by combined high-dosed antimuscarinics without increased side-effects. Eur Urol 2008; 53(5): 1021-1028
30. Gacci M, Del Popolo G, Macchiarella A et al. Vardenafil improves urodynamic parameters in men with spinal cord injury: results from a single dose, pilot study. J Urol 2007; 178 (5): 2040- 2043
31. Chancellor MB, Rivas DA, Staas WE Jr. DDAVP in the urological management of the difficult neurogenic bladder in spinal cord injury: preliminary report. J Am Paraplegia Soc 1994; 17 (4): 165-167
32. Valiquette G, Herbert J, Maede-D’Alisera P. Desmopressin in the management of nocturia in patients with multiple sclerosis. A double-blind, crossover trial. Arch Neurol 1996; 53 (12): 1270- 1275
33. Fowler CJ, Beck RO, Gerrard S et al. Intravesical capsaicin for treatment of detrusor hyperreflexia. J Neurol Neurosurg Psychiatry 1994; 57(2): 169-173
34. Fowler CJ, Jewkes D, McDonald WI et al. Intravesical capsaicin for neurogenic bladder dysfunction. Lancet 1992; 339 (8803): 1239
35. De Seze M, Wiart L, Joseph PA et al. Capsaicin and neurogenic detrusor hyperreflexia: a double-blind placebo-controlled study in 20 patients with spinal cord lesions. Neurourol Urodyn 1998; 17 (5): 513–523
36. De Ridder D, Chandiramani V, Dasgupta P et al. Intravesical capsaicin as a treatment for refractory detrusor hyperreflexia: a dual center study with long-term follow-up. J Urol 1997; 158 (6): 2087-2092
37. Chancellor MB, De Groat WC. Intravesical capsaicin and resiniferatoxin therapy: spicing up the ways to treat the overactive bladder. J Urol 1999; 162(1): 3-11
38. Giannantoni A, Di Stasi SM, Stephen RL et al. Intravesical capsaicin versus resiniferatoxin in patients with detrusor hyperreflexia: a prospective randomized study. J Urol 2002; 167(4): 1710-1714
39. Kuo HC. Effectiveness of intravesical resiniferatoxin in treating detrusor hyper-reflexia and external sphincter dyssynergia in patients with chronic spinal cord lesions. BJU Int 2003; 92 (6): 597-601.
40. Coffield JA, Simpson LL. The site and mechanism of action of botulinum neurotoxin. In: Jankovic J, Hallet M, eds. Therapy With Botulinum Toxin. Marcel Dekker, New York, 1994: 3–13
41. Мазо ЕБ, Кривобородов ГГ. Гиперактивный мочевой пузырь. Вече, М., 2003; 160
42. Schurch B, Stohrer M, Kramer G et al. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol 2000; 164 (3): 692-697
43. Rajkumar GN, Conn IG. Botulinum toxin: a new dimension in the treatment of lower urinary tract dysfunction.Urology 2004; 64 (1): 2-8
44. Madersbacher H, Wyndaele JJ, Igawa Y et al. Conservative management in neuropatic urinary incontinence. In: Abrams P, Cardozo L, Khoury S, Wein A, eds. Incontinence: 2st International Consultation on Incontinence, July 1-3, 2002, 2nd ed. Health Publication Ltd, Plymouth, UK, 2002; 697-754
45. Abrams P, Amarenco G, Bakke A et al. Tamsulosin: efficacy and safety in patients with neurogenic lower urinary tract dysfunction due to suprasacral spinal cord injury. J Urol 2003; 170 (4): 1242-1251
Рецензия
Для цитирования:
Аль-Шукри С., Кузьмин И.В., Лукина Е.Е. МЕДИКАМЕНТОЗНОЕ ЛЕЧЕНИЕ БОЛЬНЫХ С НЕЙРОГЕННОЙ ГИПЕРАКТИВНОСТЬЮ МОЧЕВОГО ПУЗЫРЯ. Нефрология. 2012;16(1):57-62. https://doi.org/10.24884/1561-6274-2012-16-1-57-62
For citation:
Al-Shukri S., Kuzmin I.V., Lukina E.E. PHARMACEUTICAL TREATMENT OF PATIENTS WITH NEUROGENIC OVERACTIVE BLADDER. Nephrology (Saint-Petersburg). 2012;16(1):57-62. (In Russ.) https://doi.org/10.24884/1561-6274-2012-16-1-57-62
Просмотров:
482
Послать статью по эл. почте 